Medical News

RSS

IDRI, Aeras partner to develop new TB vaccine candidate

Aeras and the Infectious Disease Research Institute (IDRI) announce today a new agreement to conduct joint development activities with respect to IDRI's novel tuberculosis vaccine candidate. This collaboration reflects the missions of the two non-profit product development partnerships to use cutting-edge science to develop products that address critical diseases of underserved populations around the world, including tuberculosis.

10 May 2012

Dehaier Medical first quarter revenues increase 12.3% to $3.3 million

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products, today announced its financial results for its first quarter ended March 31, 2012.

10 May 2012

Chronic exposure to cocaine drives structural changes in the brain

Chronic exposure to cocaine reduces the expression of a protein known to regulate brain plasticity, according to new, in vivo research on the molecular basis of cocaine addiction. That reduction drives structural changes in the brain, which produce greater sensitivity to the rewarding effects of cocaine.

10 May 2012

G&D, IAVI and GMI partner to develop new HIV/AIDS vaccine

The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC (G&D) today announced a collaboration to develop an AIDS vaccine using novel compounds that mimic carbohydrates, called glycomimetics.

10 May 2012

FDA AAC recommends approval of Pfizer’s tofacitinib for RA

Pfizer Inc. announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

10 May 2012

New non-embryonic stem cell treatment for cancer and leukaemia

A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.

10 May 2012

Vocera first quarter revenue increases 26% to $23.1 million

Vocera Communications, Inc., a provider of mobile communication solutions focused on addressing critical communication challenges facing hospitals, today announced results for its first quarter that ended March 31, 2012.

10 May 2012

BP sunscreens may increase risk of endometriosis in women

Scientists are reporting a possible link between the use of sunscreen containing a certain ingredient that mimics the effects of the female sex hormone estrogen and an increased risk of being diagnosed with endometriosis, a painful condition in which uterine tissue grows outside the uterus. They describe the report, published in ACS' journal Environmental Science & Technology, as the first to examine whether such a connection may exist.

10 May 2012

Warfarin may not be as effective in elderly women with AF

Older women who have been diagnosed with an irregular heart beat are at higher risk of stroke than men. A new study led by the Research Institute of the McGill University Health Centre (RI MUHC) shows that warfarin, the most common anticoagulant therapy used to prevent stroke in patients with Atrial fibrillation (AF) may not be as effective in women, 75 years or older, as in men.

10 May 2012

MSU researcher wins Grand Challenges Explorations grant for work on TB

For his work on developing new treatments for tuberculosis, a Michigan State University researcher has been named a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

10 May 2012

Resverlogix completes RVX-208 Phase 2b trial on CVD

Resverlogix Corp. is pleased to announce that dosing in SUSTAIN, a Phase 2b clinical trial to assess lipid trends and safety of RVX-208, has been completed on schedule.

10 May 2012

Cross Country Healthcare first quarter revenue increases 4% to $126.7M

Cross Country Healthcare, Inc. today reported revenue of $126.7 million in the first quarter ended March 31, 2012, a 4% increase from revenue of $122.0 million in the prior year quarter and a 2% increase sequentially from the fourth quarter of 2011.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Shire, Cosmo and Giuliani International file suit against Watson over generic Lialda

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda.

10 May 2012